Oncology has always been the priority therapeutic area for Cmed. The company originated as a data firm, when our first employees were dedicated to oncology projects and over the following 20 years we have grown significantly into a full service global CRO specialising in oncology.
This journey has had many milestones:
In 2001, we worked with a top pharma sponsor to support them with a 1000-patient oncology study, that later led to FDA approval for a highly successful leukemia treatment.
Glioblastoma, also known as glioblastoma multiforme, can be very difficult to treat and a cure is often not possible. It is an aggressive type of cancer that can occur in the brain or spinal cord and it can develop at any age, but tends to occur more often in older adults. The global incidence rate of Glioblastoma is average survival rate of 14-15 months post diagnosis. Traditionally, survival from a GBM is less than a year, and patients typically live less than six months after recurrence.
Radiopharmaceutical (RP) studies are not your average clinical trial. For me, running these trials feels very similar to developing highly sophisticated recipes. If you like your trial meaty, with complex deep flavours and a sprinkling of chilli, you’ve found your ideal dish!
With the RP space expanding, Sponsors are looking for teams with the experience it takes to turn their synopsis into a fully rounded protocol with the maximum chance of success.